ClinicalTrials.Veeva

Menu

Aminoterminal Propeptide of Type III Procollagen and Severity of Coronary Artery Disease in Patients Without Myocardial Infarction

National Taiwan University logo

National Taiwan University

Status

Completed

Conditions

Coronary Artery Disease

Study type

Observational

Funder types

Other

Identifiers

NCT00172432
9361700303

Details and patient eligibility

About

Background: Myocardial fibrosis is a major component in cardiac remodeling in patients with myocardial infarction or hibernation. However, the association of cardiac fibrosis and coronary artery disease (CAD) in patients without infarction or hibernation is still unclear. In the present study, we analyzed the relationship between serum concentrations of procollagen propeptides and severity of CAD in such patients. Patients and methods: Forty-six patients (32 men and 14 woman; mean age 64 years) with chest pain and normal left ventricular contractility were enrolled into this study. Myocardial infarction was excluded by history and electrocardiograms. All patients received stress thallium-201 single photon emission computed tomography (SPECT) and analysis of the serum levels of the aminoterminal propeptide of type I and III procollagen (PINP and PIIINP).

Sex

All

Ages

50 to 75 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • We prospectively studied 46 consecutive patients aged 50 to 75 years (32 men and 14 women; mean age was 64 years) who were referred for chest pain evaluation.

Exclusion criteria

  • MI was excluded by history and electrocardiograms. Regional wall motion abnormalities and impaired left ventricular contractility (left ventricular ejection fraction < 50%) were excluded by routine echocardiography.

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems